CellType vs Insilico Medicine
Insilico Medicine holds the stronger position because it has real revenue, a large cash balance, and paying pharma partners, while CellType is a two person team with $500K and no visible customers yet.
CellType
Two-person startup using LLMs to simulate cell biology for drug discovery
Insilico Medicine
AI platform that designs new drugs and licenses them to big pharma
Dimension by dimension
| Dimension | CellType | Insilico Medicine |
|---|---|---|
| Staying power of the core product | CellType is a two person startup with $500K raised and no disclosed pharma partnerships, running on an open model rather than its own. | Insilico Medicine already licenses drugs it designs to big pharma and posted $56.24 million in FY2025 revenue. |
| Exposure to AI absorbing the product | CellType's simulation work relies on AI agents running on an open Google model rather than proprietary technology, leaving it exposed to being absorbed by general AI tools. | Insilico Medicine's drug design and pharma licensing process goes beyond what a general AI model would replace, giving it only partial exposure. |
| How easily a giant could copy them | CellType could be readily copied by a larger competitor, given its tiny two person team and reliance on an open, publicly available model. | Insilico Medicine would be harder for a giant to replicate, since it has built its own drug design platform and partnership pipeline. |
| Pressure from rivals | CellType faces heavier direct pressure than Insilico Medicine, competing against better funded rivals like Isomorphic Labs, Chai Discovery, and Insilico Medicine itself for pharma deals it has not yet secured, as assessed July 2026. | Insilico Medicine faces lighter pressure, mainly from Isomorphic Labs chasing the same partnership dollars, with no proven loss of customers, as assessed July 2026. |
| Financial footing | CellType has raised $500K total and employs two people, with no revenue figures disclosed. | Insilico Medicine holds $393.3 million in cash and bank balances and expects $102.5 million to $106.5 million in revenue for H1 2026. |
| Underlying defensibility | CellType remains in an early stage, dependent on an open model with no unique technology of its own yet. | Insilico Medicine has an established drug design platform and existing licensing relationships, giving it a stronger defensive position. |
Questions people ask
- CellType vs Insilico Medicine, which one is in a stronger spot right now?
- Insilico Medicine is in the stronger spot. It has $56.24 million in FY2025 revenue and $393.3 million in cash, while CellType is a two person team that has only raised $500K and has no disclosed pharma deals.
- Is CellType at risk of being replaced by AI itself?
- Yes, more so than Insilico Medicine. CellType runs on an open Google model with agents on top, which is rated likely to be absorbed by future AI, while Insilico Medicine's own drug design and licensing process is only partly exposed.
- Could a large company just copy what CellType or Insilico Medicine does?
- Copying CellType is rated likely since it depends on an open model and has no scale of its own. Copying Insilico Medicine is only rated possible, since it has built its own platform and pharma partnerships over time.
- Who is CellType actually competing against?
- CellType is competing against better funded players including Isomorphic Labs, Chai Discovery, and Insilico Medicine, all of whom are locking down pharma partnerships that CellType has not yet secured.
- Does Insilico Medicine have any real revenue or is it still speculative?
- Insilico Medicine has real revenue, reporting $56.24 million for FY2025 and expecting $102.5 million to $106.5 million in the first half of 2026. CellType has no revenue figures disclosed at all.
Other comparisons with these companies